REGORAFENIB for Rectal cancer (locally-advanced, stage II-III)

Inclusion criteria

• {"criterion_text":"- Female or Male\n- Age ≥ 18 years old\n- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n- Histologically or cytologically verified adenocarcinoma of the rectum\n- Tumour with distal border below the peritoneal reflection and within 15 cm from the anal verge\n- Stage cT3/T4a and Nany or cT1-2 and N+ as documented by baseline pelvic MRI\n- Absence of distant metastases as shown by baseline computed tomography (CT) of the thorax-abdomen or CT scan of the thorax and MRI of the abdomen\n- Adequate haematological function as defined by absolute neutrophil count (ANC) ≥1.5 × 109/L, platelet count ≥100 × 109/L, and haemoglobin ≥9 g/dL\n- Adequate hepatic function as defined by a total bilirubin level ≤1.5 × the upper limit of normal (ULN) range (excluding subjects with known Gilbert’s syndrome), and alanine aminotransferase (ALT) levels ≤2.5 × ULN\n- Adequate renal function as defined by an estimated creatinine clearance ≥30 mL/min according to the Cockcroft-Gault or Wright formula\n- Negative serum pregnancy test at screening (up to 7 days before treatment start) for women of childbearing potential\n- Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least 7 months after the last administration of study treatment.\n- Men with childbearing potential partner must agree to use condom during the course of this study and for at least 5 months after the last administration of the study treatment.\n- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n- Absence of clinical conditions that, in the opinion of the investigator, would contraindicate neoadjuvant therapy and/or surgery\n- Life expectancy of at least 3 months\n- Completion of all necessary screening procedures within 28 days prior to enrolment.\n- Signed Informed Consent form (ICF) obtained prior to any study related procedure."}

Exclusion criteria

• {"criterion_text":"- Any prior or concurrent surgery, chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for rectal cancer. Concurrent use of hormones for noncancer-related conditions (i.e., insulin for diabetes and hormone replacement therapy) is acceptable.\n- Prior myocarditis\n- Known history of immune colitis, immune pneumonitis, pulmonary fibrosis or other medical conditions (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject’s tolerance of trial treatment\n- Vaccination within 28 days of the first dose of study treatment and while on trial (except for administration of inactivated vaccines)\n- Other invasive malignancy within 2 years except for non-invasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured. Anti-neoplastic treatment received in the past for malignancies cured 2 or more years before enrolment are permitted.\n- Any investigational anti-cancer therapy other than the protocol specified therapies.\n- Strong inhibitors of CYP3A4 activity (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin and voriconazole), strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal, and niflumic acid), and strong inducers of CYP3A4 (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital and St. John’s wort) from 28 days before study enrolment up to the end of study treatment.\n- Major surgery within 28 days of the first dose of study treatment\n- Presence of gastrointestinal perforation or fistula\n- Any contraindication to pelvic irradiation as evaluated by the investigator\n- Prior organ transplantation, including allogeneic stem cell transplantation\n- Clinically significant acute or chronic infections including, among others: - known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) - known history of testing positive for hepatitis B virus (HBV) surface antigen or anti-hepatitis C virus (HCV) antibody and confirmatory HCV ribonucleic acid (RNA) test\n- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent (subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible)\n- Systemic corticosteroids administered as hormone replacement or as immunosuppressants at doses exceeding 10 mg/day of prednisone or equivalent. Other immunosuppressive medications including, but not limited to methotrexate, azathioprine, and TNF-α blockers. Use of immunosuppressive medications for the management of treatmentrelated AEs or in subjects with contrast allergies is acceptable. A temporary period of steroids is allowed for different indications, at the discretion of the investigator (i.e., chronic obstructive pulmonary disease, radiation, nausea, etc.). Administration of steroids through a route known to result in a minimal systemic exposure [topical, intranasal, intro-ocular, or inhalation] is acceptable\n- Known severe hypersensitivity reactions to the investigational treatments, or any excipients or non-investigational medicinal products or concomitant medications\n- Pregnant and/or lactating women\n- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, uncontrolled arterial hypertension, or serious cardiac arrhythmia requiring medication"}

Primary endpoints

• {"endpoint_text":"- Complete response (CR) rate (including either pathological [pCR] or clinical complete response [cCR]) in subjects with pMMR/MSS tumours","definition_or_measurement_approach":"Complete response (CR) defined as either pathological complete response (pCR) or clinical complete response (cCR) in subjects with pMMR/MSS tumours; measured as the CR rate."}

Secondary endpoints

• {"endpoint_text":"- CR rate in the mMiITT population (including both pMMR/MSS and dMMR/MSI-H tumours)","definition_or_measurement_approach":"CR rate in the mMiITT population (including both pMMR/MSS and dMMR/MSI-H tumours)."}
• {"endpoint_text":"- Toxicity","definition_or_measurement_approach":"Toxicity (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Compliance to treatment","definition_or_measurement_approach":"Compliance to treatment (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- R0 resection rate","definition_or_measurement_approach":"R0 resection rate (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Pathological tumour regression grade (pTRG)","definition_or_measurement_approach":"Pathological tumour regression grade (pTRG) (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Local recurrence rate","definition_or_measurement_approach":"Local recurrence rate (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Distant recurrence rate","definition_or_measurement_approach":"Distant recurrence rate (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Event-free survival (EFS)","definition_or_measurement_approach":"Event-free survival (EFS) (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- Overall survival (OS)","definition_or_measurement_approach":"Overall survival (OS) (no further definition provided in the endpoint list)."}
• {"endpoint_text":"- CD3 and CD8 T-cells infiltrate increase in post-treatment tumour tissue samples","definition_or_measurement_approach":"CD3 and CD8 T-cell infiltrate increase measured in post-treatment tumour tissue samples (no detailed assay/threshold defined in the endpoint list)."}

Belgium

Earliest CTIS Part Ii Submission Date

23-08-2024

Latest Decision Or Authorization Date

01-10-2025

Processing Time Days

404

Number Of Sites

10

Number Of Participants

90

Primary sponsor

Full Name

Institut Jules Bordet

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Belgium

Third parties

• {"country":"","full_name":"Bayer AG","duties_or_roles":"Monetary support","organisation_type":""}